ESR1 and breast carcinoma: Clinically, this reactivation of ERα enhances chemosensitivity to tamoxifen, an anti-estrogen drug, in ERα-negative breast cancer cells, suggesting a potential clinical therapeutical application of combination of EGCG with a histone deacetylase inhibitor in breast cancer.